Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by University of Thessaly.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
University of Thessaly
ClinicalTrials.gov Identifier:
NCT00935285
First received: July 8, 2009
Last updated: NA
Last verified: July 2009
History: No changes posted
  Purpose

Ventilator-associated pneumonia (VAP) is very common in the intensive care unit (ICU), affecting 9 to 40% of ICU patients and mortality rates range from 20 to 50% and may reach more than 70% when the infection is caused by multi-resistant and invasive pathogens. The most common pathogens that cause VAP are the Gram(-) bacteria. Findings indicate that TLRs serves as an important signal in the generation of protective innate responses to bacterial pathogens of the lung and that is required for effective innate immune responses against Gram-negative bacterial pathogens. There is genetic evidence that mutations in TLRs increase the risk of developing nosocomial infections. Understanding the TLR system should offer invaluable opportunity for manipulating host immune responses.


Condition
Ventilator-Associated Pneumonia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Immune Response in Patients Who Develop Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU) and the Role of Toll-Like Receptors(TLR2,TLR4,TLR9).

Resource links provided by NLM:


Further study details as provided by University of Thessaly:

Estimated Enrollment: 300
Study Start Date: July 2009
Estimated Study Completion Date: August 2011
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   14 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

This study will include ICU patients who receive mechanical ventilation <48h and have no history of ΑRDS or other respiratory disease.

Criteria

Inclusion Criteria:

  • Presence in intensive care unit receive mechanical ventilation <48h have no history of ΑRDS or other respiratory disease

Exclusion Criteria:

  • Length of stay <24 hours
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00935285

Locations
Greece
Zakynthinos
Larisa, Mezourlo, Greece, 41335
Sponsors and Collaborators
University of Thessaly
Investigators
Principal Investigator: Sofia Sarafi RN MSc, ICU University Hospital Larisa
  More Information

No publications provided

Responsible Party: ZAKYNTHINOS E, INTENSIVE CARE UNIT DEPARTMENT UNIVERSITY HOSPITAL OF LARISA
ClinicalTrials.gov Identifier: NCT00935285     History of Changes
Other Study ID Numbers: 1692UT
Study First Received: July 8, 2009
Last Updated: July 8, 2009
Health Authority: Greece: Ethics Committee

Keywords provided by University of Thessaly:
Ventilator-associated pneumonia (VAP)
Intensive care unit (ICU)
Toll-like receptors

Additional relevant MeSH terms:
Pneumonia
Pneumonia, Ventilator-Associated
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Cross Infection
Infection
Ventilator-Induced Lung Injury
Lung Injury

ClinicalTrials.gov processed this record on September 18, 2014